Ained from pigs that CDK4 Inhibitor Biological Activity overcome PRRSV acute infection. Exosomes were obtained by a mixture of ultracentrifugation and size exclusion chromatography and characterized by BCA, Flow cytometry, nanosight, Cryo-TEM and proteomic analyses. Animals have been vaccinated with exosomes and/or viral peptides identified by proteomics in mixture with Montanide. Immune responses have been measured by a commercial ELISA (IDEXX X3 PRRSV), by an indirect in-house ELISA and by IFN- ELISPOT. Results: No clinical symptoms or adverse effects have been observed in animals infected with up-to two mg of exosomes, unequivocally demonstrating that this vaccine formulation is cost-free of virus and secure. ELISA analysis demonstrated that immunizations elicited certain humoral IgG immune responses, albeit variably. Yet, sera from these same vaccinated animals was diagnosed totally free of virus applying a commercial test; thus, indicating that this vaccine method is in a position to differentiate vaccinated from infected animals. Final, priming the animals with exosomes from convalescence animals and boosting them with synthetic peptides identified by MS related with them, elicited distinctive and higher IFN- immune response when stimulated with viral peptides (around 400 SFCx106 PBMCS). Summary/Conclusion: Altogether, our data help additional development of plasma-derived exosomes from convalescence animals as a novel antigen discovery and vaccine tactic against PRRSV. Funding: SMT have an Industrial PhD fellow by Government of Catalonia (AGAUR) as portion of a collaborative agreement among INNOVEX THERAPEUTICS SL along with the University of Lleida (Id No 2014 DI 044).OF18.Chitosan coated extracellular Dopamine Receptor Antagonist Source vesicles as an adjuvant for immunization against salmonid rickettsial septicemia in an adult zebrafish model Julia Tandberg1; Leidy Lagos2; Erik Ropstad3; Gro Smistad1; Marianne Hiorth1; Hanne Cecilie Winther-Larsen1 University of Oslo, Oslo, Norway; 2Norwegian University of life science, Moss, Norway; 3Norwegian University of Life Sciences, Oslo, NorwayOF18.ARMMs as a versatile platform for intracellular delivery of macromolecules Qiyu Wang; Quan Lu Harvard University, Boston, MA, USABackground: Majority of disease-modifying therapeutic targets are restricted for the intracellular space and are for that reason not druggable employing existing biologic modalities. The ability to effectively deliverBackground: Extracellular bacterial vesicles (EVs) are 5050 nm spherical structures secreted from the surface of numerous bacteria. Proteomic and biochemical characterization has revealed that the vesicles include a number of bacterial elements, including proteins, lipopolysaccharides, DNA and RNA. This makes MVs exciting as possible vaccine candidates, as they represent many aspects with the bacteria, but within a nonreplicative form. EV-based vaccines have, in addition, been successfully used for epidemic control in against serogroup B meningococcal disease, but you’ll find nonetheless little known concerning the use of EV-based vaccines in other animals. The present study focused on evaluating extracellular vesicles coated with chitosan as a possible vaccine candidate against the intracellular pathogen Piscirickettsia salmonis applying an adult zebrafish infection model. Techniques: For the dose-response experiment 25 fish per group had been injected with ten, 20 or 40 of chitosan coated EVs (cEVs) or 20 phosphate buffer (manage group) by i.p. injections, utilizing a 27 g needle. For the immunization experiment 65 fish per group were i.